[Primary intestinal lymphangiectasia: twenty years of experience at a Mexican tertiary care hospital].

Rev Gastroenterol Mex

Servicio de Gastroenterología y Nutrición, Instituto Nacional de Pediatría, Secretaría de Salud, México, D.F., México.

Published: June 2015

Background: Primary intestinal lymphangiectasia is a rare congenital disease described by Waldmann in 1961 that is a consequence of obstruction of the lymphatic drainage of the small bowel with secondary lymph vessel dilation. This distorts the architecture of the villi and causes a leakage of lymph into the intestinal lumen, resulting in protein-losing enteropathy and malabsorption.

Aim: To describe the clinical, biochemical, radiologic, endoscopic, and histologic characteristics in children with primary intestinal lymphangiectasia.

Method: A retrospective observational, descriptive, cross-sectional study was conducted that reviewed the case records of children diagnosed with primary intestinal lymphangiectasia that were seen at the Department of Gastroenterology and Nutrition of the Instituto Nacional de Pediatría within the time frame of January 1, 1992 to September 30, 2012.

Results: Four patients were found that presented with primary intestinal lymphangiectasia. Three of them had been diagnosed before 3 years of age. All the patients presented with chronic diarrhea, edema, lymphopenia, hypocalcemia, and hypogammaglobulinemia, and 3 patients presented with hypocholesterolemia. Bowel transit time, endoscopy, and intestinal biopsies were characteristic of this pathology.

Conclusions: Intestinal lymphangiectasia should be suspected when there is a clinical picture of chronic diarrhea and protein-losing enteropathy accompanied with edema at any level, as well as hypoalbuminemia, hypocalcemia, lymphopenia, hypogammaglobulinemia, and hypocholesterolemia, which are the main biochemical findings of this pathology. All children presenting with intestinal lymphangiectasia should undergo an upper gastrointestinal series with bowel transit time and endoscopy with biopsies taken at the level of the duodenum. Treatment includes diet and the periodic administration of albumin and gamma globulin.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rgmx.2013.07.007DOI Listing

Publication Analysis

Top Keywords

intestinal lymphangiectasia
24
primary intestinal
16
patients presented
12
intestinal
8
protein-losing enteropathy
8
chronic diarrhea
8
bowel transit
8
transit time
8
time endoscopy
8
lymphangiectasia
6

Similar Publications

Lymphangiogram in primary intestinal lymphangiectasia.

Indian J Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576 104, India.

View Article and Find Full Text PDF

Effects of corn oil ingestion on the intestinal mucosa of normal dogs.

Front Vet Sci

December 2024

Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, Jinju, Republic of Korea.

Introduction: We assessed corn oil's oral effectiveness in detecting small bowel changes in healthy dogs through ultrasonography, endoscopy, and histopathology. We hypothesize that corn oil ingestion will not significantly increase the visibility of lymphatics and lacteals in healthy dogs.

Methods: Five healthy male beagles were studied under institutional guidelines.

View Article and Find Full Text PDF

Case 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia.

Radiology

December 2024

From the Department of Radiology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054.

History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.

View Article and Find Full Text PDF

An evaluation of pozelimab for the treatment of CHAPLE disease.

Expert Opin Biol Ther

January 2025

Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, Marmara University, Istanbul, Turkey.

Introduction: CHAPLE disease is a severe, ultra-rare disorder caused by CD55 gene mutations, leading to uncontrolled complement hyperactivation, protein-losing enteropathy, and systemic thrombosis. Recent advances in targeted therapies, particularly the C5 inhibitor pozelimab (Veopoz), offer new treatment options by addressing complement dysregulation, marking a shift from symptomatic to precision therapy.

Areas Covered: This review explores the pathophysiology, clinical manifestations, and current treatments for CHAPLE disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!